Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#3504 Telotristat ethyl affects crosstalk between tumor cells and stromal fibroblasts in small intestinal neuroendocrine tumors (SI-NETs)

Introduction: SI-NETs are often associated with mesenteric fibrosis (MF) which causes significant morbidity and mortality. Telotristat ethyl (TE) was developed to treat carcinoid syndrome in SI-NET patients however, recent studies indicated TE could also have anti-tumor activity, the mechanism for which remains unclear.

Conference:

Presenting Author:

Authors: Hodgetts H, Martins M, Chen L, Laskaratos F, Hall A,

Keywords: fibrosis, fibroblast, crosstalk, telotristat, intestine, small, tumor,

#2971 A Retrospective Multicentre Evaluation of the Outcomes and Management of Carcinoid Heart Disease in Patients with Advanced Midgut NETs: A NET-CONNECT Descriptive Study

Introduction: Carcinoid heart disease (CHD) is a poor prognostic factor in neuroendocrine tumours (NETs). However, the extreme variability of diagnostic and treatment approaches reported in literature account for uncertainties on the best management in this selected population.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Spada F

Authors: Spada F, Laskaratos F, Crona J, Oleinikov K, Zandee W,

Keywords: Carcinoid Heart Disease, NETs, Carcinoid Syndrome, Midgut NETs,

#2055 Antiproliferative Effect of Above-Label Doses of Somatostatin Analogues (SSA) for the Management of Neuroendocrine Tumors (NETs)

Introduction: Escalated doses of SSA have been used for control of refractory symptoms and tumour growth

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Laskaratos F, Shah R, Banks J, Smith J, Jacobs B,

Keywords: above-label somatostatin analogues, neuroendocrine tumor,

#2027 Predictors of Antiproliferative Effect of Lanreotide Autogel (LA) as First-Line Therapy for Advanced Neuroendocrine Tumors (NETs)

Introduction: The antiproliferative properties of LA in GEP NETs were demonstrated in the recently published CLARINET study

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Laskaratos F, Megapanou M, Papantoniou D, Hayes A, von Stempel C,

Keywords: lanreotide, neuroendocrine tumor,

#1796 Typical Bronchial Neuroendocrine Tumours with Advanced Disease: A Misleading Biology

Introduction: Bronchial NETs are graded by histological classification into ‘typical’, ‘atypical’ NETs or small and large neuroendocrine carcinoma’s. Typical NETs are regarded as being low-grade malignant however metastatic disease can still develop.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Diamantopoulos L

Authors: Diamantopoulos L, Demetriou G, Laskaratos F, Caplin M, Toumpanakis C,

Keywords: Bronchial, Typical,